Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule Statement of Significance: Thirty-six bivalent biparatopic antibodies targeting pairs of nine distinct topographical epitopes distributed over CD30 were de

New Research (2025 Paper): "Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule" from Japan

doi.org/10.1093/abt/...

#CD30 #TNFRSF8 #Biparatopic #Bispecific #Oncology

FDA grants accelerated approval to zanidatamab-hrii On November 20, 2024, the FDA granted accelerated approval to zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals, Inc.) for biliary tract cancer.

I am extremely happy and excited to see that a drug that we developed at Zymeworks was just approved by the FDA.

#biparatopic #bispecific #antibody #Oncology #Immunotherapy #BiparatopicAntibodies #HER2 #InnovationInScience

www.fda.gov/drugs/resour...